Investigators take part in training

Issue: October 25, 2012

Four oncology researchers were accepted into the 2012 SWOG Young Investigator Training Course.

Each fall, selected applicants attend the intensive 3-day workshop to learn how to develop and conduct multi-side clinical trials within NCI’s cooperative group network. More than 60 researchers have completed the course, which includes instruction in protocol development, trial management and statistical analysis.

Investigators must present research proposals during the application process, and those proposals are refined during the workshop.

This year’s investigators and their proposals are:

Christopher Lieu, MD, assistant professor at University of Colorado Cancer Center, who proposed a phase 2 trial that compares the MEK inhibitor TAK-733 with standard chemotherapy in patients with KRAS-mutant, PI3K wild-type metastatic colorectal cancer.
William Lowrance, MD, MPH, assistant professor at University of Utah Huntsman Cancer Institute, who proposed a phase 2 trial of dutasteride with or without intermittent MDV3100 to extend time to progression for men with prostate cancer.
Jatin Shah, MD, assistant professor at The University of Texas MD Anderson Cancer Center, who proposes a phase 3 trial of lenalidomide with and without the oral proteasome inhibitor MLN9708 as maintenance therapy for patients with multiple myeloma who underwent autologous stem cell transplant.
William Nassib William Jr., MD, assistant professor at The University of Texas MD Anderson Cancer Center, who proposed a randomized phase 2 study of neoadjuvant cisplatin and docetaxel with or without nintedanib for patients with resectable non–small cell lung cancer.